Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

Dolutegravir (DTG) based dual therapies for treating PLWHIV are a standard of care nowadays. Switching to DTG and lamivudine (3TC) safety and efficacy were proven in TANGO randomized clinical trial. This multicenter retrospective study included 1032 HIV virologically suppressed patients switching to...

Descripción completa

Detalles Bibliográficos
Autores principales: Buzón, Luis, Dueñas, Carlos, Pedrero, Roberto, Iribarren, Jose Antonio, de los Santos, Ignacio, Díaz de Santiago, Alberto, Morán, Miguel Ángel, Pousada, Guillermo, Moreno, Estela, Ferreira, Eva, Iglesias, Alicia, Martín, Cristina, Gómez, Julia, Rodríguez, Laura, Egido, Miguel, Sepulveda, María-Antonia, Troya, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963008/
https://www.ncbi.nlm.nih.gov/pubmed/36851536
http://dx.doi.org/10.3390/v15020322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963008/
https://www.ncbi.nlm.nih.gov/pubmed/36851536
http://dx.doi.org/10.3390/v15020322

Ejemplares similares